Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn Sells 2,681 Shares

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,681 shares of the firm’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $111,422.36. Following the transaction, the chief operating officer now owns 237,640 shares in the company, valued at approximately $9,876,318.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The shares were sold at an average price of $43.09, for a total value of $97,426.49.
• On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total transaction of $296,636.65.

Twist Bioscience Trading Up 5.3 %

Shares of TWST stock opened at $45.42 on Thursday. The company’s fifty day moving average price is $43.64 and its 200-day moving average price is $45.43. The stock has a market cap of $2.66 billion, a PE ratio of -11.89 and a beta of 1.78. Twist Bioscience Co. has a 12 month low of $15.85 and a 12 month high of $60.90.

Analyst Ratings Changes

TWST has been the topic of several recent analyst reports. JPMorgan Chase & Co. raised their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Robert W. Baird boosted their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. Leerink Partners upped their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Barclays cut their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Finally, Evercore ISI upped their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $51.22.

Institutional Investors Weigh In On Twist Bioscience

Hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Twist Bioscience by 30.7% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 156,288 shares of the company’s stock valued at $5,362,000 after purchasing an additional 36,744 shares during the last quarter. BNP Paribas Financial Markets raised its stake in Twist Bioscience by 34.8% during the first quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock valued at $5,895,000 after buying an additional 44,349 shares during the last quarter. Jennison Associates LLC boosted its holdings in Twist Bioscience by 523.1% in the first quarter. Jennison Associates LLC now owns 150,022 shares of the company’s stock worth $5,147,000 after acquiring an additional 125,946 shares in the last quarter. Quantbot Technologies LP purchased a new stake in shares of Twist Bioscience in the first quarter worth $232,000. Finally, Swiss National Bank increased its holdings in shares of Twist Bioscience by 0.8% during the first quarter. Swiss National Bank now owns 114,000 shares of the company’s stock valued at $3,911,000 after acquiring an additional 900 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.